Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI939 + Sintilimab in Advanced Lung Cancer
NCT04672369Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Jun 2021
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tamgiblimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Innovent Biologics. Primary endpoint: Objective Response Rate at 6 months. Started Jun 2021; status: completed.
02
Drugs
tamgiblimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04672369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04672369.